A Study to Evaluate Tolerability and Efficacy of Evolocumab (AMG 145) in Japanese Subjects (AMG145)
A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate Tolerability and Efficacy of AMG 145 on LDL-C in Combination With Stable Statin Therapy in Japanese Subjects With Hypercholesterolemia and High Cardiovascular Risk
Sponsor: Amgen
This PHASE2 trial investigates Hypercholesterolemia and High Risk for Cardiovascular Events and is currently completed. Amgen leads this study, which shows 10 recorded versions since 2012 — indicating substantial longitudinal coverage. Heart and vascular conditions benefit from the kind of long-term tracking this trial provides.
Status Flow
Change History
10 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE2
-
Dec 2018 — Jan 2021 [monthly]
Completed PHASE2
▶ Show 5 earlier versions
-
Sep 2018 — Dec 2018 [monthly]
Completed PHASE2
-
Jun 2018 — Sep 2018 [monthly]
Completed PHASE2
-
May 2017 — Jun 2018 [monthly]
Completed PHASE2
-
Feb 2017 — May 2017 [monthly]
Completed PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE2
First recorded
Jul 2012
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Amgen
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Bunkyo-ku, Japan , Chiyoda-ku, Japan , Chuo-ku, Japan , Fujioka-shi, Japan , Fukui-shi, Japan , Gifu, Japan , Hachioji-shi, Japan , Hanyu-shi, Japan , Hitachi-shi, Japan , Ibaraki-shi, Japan and 25 more locations